Menu
Washingtoner
  • Home
  • Health
  • Technology
  • Artificial Intelligence
  • Real Estate
  • Non-profit
  • Longevity
  • Music
  • Software
Washingtoner

Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024
Washingtoner/10255123

Trending...
  • Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
  • Spokane: "Keep Kids Moving" – A Fund to Help Replace Recreation and Sports Gear
  • Spokane Police Officers Arrest "Grave Robber"
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.

On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.

Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.

More on Washingtoner
  • Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
  • Longevity Academy Announces J.P. Medved of Longevity Advice as Next Guest in the Longevity Leaders
  • Medcurity Introduces a Better Way for Healthcare and Its Vendors to Build Trust
  • Haven Treatment Center Now In-Network Partnership with Aetna, Expanding Access to Youth Health Care
  • Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board

In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.

The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.

Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
  • DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
  • TBM Council Establishes TBM as The Business Operating System for AI
  • Spokane: SFD's 8th Annual Kids Jr Firefighter Academy
  • Tacoma Dome Unveils Salish Mural
  • French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
  • Tacoma: Northbound I-705 Stadium Way Off-Ramp to Close at Noon Today for Emergency Repairs
  • LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
  • PeopleNTech LLC to Participate in CWS Summit North America 2026
  • Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • Tidy-Up Tacoma Teams Up with Community Partners for Citywide Cleanup Event September 19
  • Lynnwood Heating LLC Helps Homeowners Take Advantage of 2026 Heat Pump Installation Rebates
  • Tacoma: Applicants Sought for the Board of Ethics
  • Tacoma: Applicants Sought for the Landmarks Preservation Commission
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • Tacoma: Arrest Made in 2021 Homicide
  • Share your workplace safety solutions at 2027 Applied Ergonomics Conference
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: SPD Arrest Level III Registered Sex Offender for Failure to Register - 591
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support - 221
  • On the Boards: Proform Builds Announce New Construction in Alki, Seattle - 158
  • Diginyze eCommerce ERP Module Creates Single Source of Truth for Enterprise Operations - 146
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism - 135
  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 127
  • Tacoma: Applications Now Being Accepted for a Position on the Planning Commission - 117
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 116
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 115
  • Tacoma: Hylebos Bridge Closed Today for Maintenance Work - 105

Similar on Washingtoner

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
  • Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
  • Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • ChargeOn Announces Conversational Payment Management Solution
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute